

# A Single-center, Phase II Study on Efficacy & Safety of SCRT+CAPOX+Serplulimab+Bevacizumab for MSS Rectal Cancer

NCT07347951

---

Status	RECRUITING
Phase	Phase 2
Sponsor	First Affiliated Hospital of Wenzhou Medical University
Enrollment	30 participants

## Plain Language Summary

---

This study is testing a combination treatment for rectal cancer — short-course radiation followed by chemotherapy (CAPOX), an immunotherapy drug (serplulimab), and a drug that targets blood vessel growth (bevacizumab) — as a treatment before surgery, in people with rectal cancer that is not the type that typically responds to immunotherapy alone (MSS/pMMR tumors).

### \*\*You may be eligible if...\*\*

- You are 18–75 years old
- You want to try to preserve your anal function (avoid a permanent colostomy)
- Your rectal cancer is confirmed by biopsy and is MSS, MSI-L, or pMMR type
- The tumor is within 10 cm of the anus and has not spread outside the rectum region on scans
- You have not received any prior cancer treatments

### \*\*You may NOT be eligible if...\*\*

- You have another active cancer
- Your cancer has spread to other organs or lymph nodes outside the rectal drainage area
- You need emergency surgery (e.g., bowel blockage, perforation)
- You have severe health conditions limiting your life expectancy to 5 years or less
- You have HIV or are immunocompromised

Talk to your doctor to see if this trial is right for you.

## Key Eligibility Criteria

---

### Inclusion (8)

- Patients who have a desire to preserve the anus and are willing to receive the entire course of neoadjuvant therapy.
- Aged between 18 and 75 years, with no gender restrictions.
- Diagnosed via pelvic MRI and rectoscopy with a tumor located  $\leq 10$  cm from the anal verge, with a clinical stage of cT3-4N0/+M0, and lymph nodes confined within the mesorectum.
- Histologically diagnosed with rectal adenocarcinoma; genetic testing indicates MSS or MSI-L, or immunohistochemistry of tumor biopsy indicates pMMR (positive for MSH1, MSH2, MSH6, and PMS2 proteins).
- ECOG performance status score of 0-1.

... and 3 more (see full listing online)

### Exclusion (12)

- In addition to a confirmed diagnosis of rectal cancer, there is a current or past history of active malignant tumors.
- Patients with metastases to other sites indicated by preoperative staging.
- Patients with suspicious positive lymph nodes in non-draining areas of the rectum, such as the internal and external iliac lymph nodes, as assessed by preoperative MRI or CT.

<https://clinicaltrials.gov/study/NCT07347951>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://clinicaltrials.gov). Generated by [ClinicalTrialsFinder.org](https://clinicaltrialsfinder.org).

- Patients requiring emergency surgery due to complications such as intestinal obstruction, intestinal perforation, or intestinal hemorrhage.
  - Patients with severe comorbid conditions and an estimated life expectancy of d5 years.
- ... and 7 more (see full listing online)

## Locations (1 total)

---

The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China